By Josh White
Date: Wednesday 12 Apr 2023
(Sharecast News) - Drug discovery and development company ImmuPharma announced positive progress in its late-stage P140 clinical programme on Tuesday, for patients with chronic idiopathic demyelinating polyneuropathy (CIDP), a rare neurological disease with high medical need.
By Josh White
Date: Friday 11 Nov 2022
(Sharecast News) - Drug discovery and development specialist ImmuPharma updated the market on a recent meeting in Atlanta with its United States partner Avion Pharmaceuticals on Friday, for strategic discussions around its 'Lupuzor' clinical programme.
By Josh White
Date: Wednesday 14 Sep 2022
(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Wednesday that its US partner for 'Lupuzor', Avion Pharmaceuticals, has received a written response from the Food and Drug Administration (FDA).
Currency | UK Pounds |
Share Price | 1.90p |
Change Today | -0.14p |
% Change | -6.86 % |
52 Week High | 3.42 |
52 Week Low | 0.85 |
Volume | 1,925,128 |
Shares Issued | 416.44m |
Market Cap | £7.91m |
RiskGrade | 328 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
16:28 | 419,759 @ 2.00p |
16:29 | 20,000 @ 2.00p |
16:29 | 47,619 @ 2.01p |
16:28 | 69,550 @ 2.00p |
16:28 | 250,000 @ 2.00p |
You are here: research